Invention Grant
- Patent Title: Fused pentacyclic imidazole derivatives as modulators of TNF activity
-
Application No.: US16086311Application Date: 2017-03-31
-
Publication No.: US10793578B2Publication Date: 2020-10-06
- Inventor: Jag Paul Heer , Jean Keyaerts
- Applicant: UCB Biopharma SRL , Sanofi
- Applicant Address: BE Brussels FR Paris
- Assignee: UCB Biopharma SRL,Sanofi
- Current Assignee: UCB Biopharma SRL,Sanofi
- Current Assignee Address: BE Brussels FR Paris
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@212ba5d1
- International Application: PCT/EP2017/057769 WO 20170331
- International Announcement: WO2017/167996 WO 20171005
- Main IPC: C07D487/18
- IPC: C07D487/18 ; C07D487/04 ; C07D487/22 ; A61P25/28 ; A61P37/04 ; A61P3/00 ; A61P9/00

Abstract:
A series of fused pentacyclic imidazole derivatives, being potent modulators of f benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 5,7,8,15-tetrahydro-6H-8,15-methanobenzimidazo[1,2-b][2,5]benzodiazocin-6-one derivatives and analogs thereof.
Public/Granted literature
- US20190112314A1 Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity Public/Granted day:2019-04-18
Information query